Agata Zuccaro

Ms. Agata Zuccaro

San Pablo CEU University
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2022 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
HCHéctor Cañeque-Rufo
Héctor Cañeque-Rufo
MSMaría Gracia Sánchez-Alonso
María Gracia Sánchez-Alonso
AZAgata Zuccaro
Agata Zuccaro
JSJulio Sevillano
Julio Sevillano
MRM.Pilar Ramos-Alvarez
M.Pilar Ramos-Alvarez
Gonzalo HerradonGonzalo Herradon
Gonzalo Herradon

Verified
Journal Article
Open access
PDF file
AZAgata Zuccaro
Agata Zuccaro
BZBegoña Zapatería
Begoña Zapatería
MSMaría Gracia Sánchez-Alonso
María Gracia Sánchez-Alonso
MGMaria Haro Garcia
Maria Haro Garcia
MLMaría Limones
María Limones
MRM.Pilar Ramos-Alvarez
M.Pilar Ramos-Alvarez
(1) Background: Pleiotrophin preserves insulin sensitivity, regulates adipose tissue lipid turnover and plasticity, energy metabolism and thermogenesis. The aim of this study was to determine the role of pleiotrophin in hepatic lipid metabolism and in the metabolic crosstalk between the liver and brown and white adipose tissue (AT) in a high-fat diet-induced (HFD) obesity mice model. (2) Methods: We analyzed circulating variables, lipid metabolism (hepatic lipid content and mRNA expression), brown AT thermogenesis (UCP-1 expression) and periovarian AT browning (brown adipocyte markers mRNA and immunodetection) in Ptn−/− mice either fed with standard-chow diet or with HFD and in their corresponding Ptn+/+ counterparts. (3) Results: HFD-Ptn−/− mice are protected against the development of HFD-induced insulin resistance, had lower liver lipid content and lower expression of the key enzymes involved in triacylglycerides and fatty acid synthesis in liver. HFD-Ptn−/− mice showed higher UCP-1 expression in brown AT. Moreover, Ptn deletion increased the expression of specific markers of brown/beige adipocytes and was associated with the immunodetection of UCP-1 enriched multilocular adipocytes in periovarian AT. (4) Conclusions: Ptn deletion protects against the development of HFD-induced insulin resistance and liver steatosis, by increasing UCP-1 expression in brown AT and promoting periovarian AT browning.

2 December 2025 in bioRxiv
Verified
Preprint
Open access
HCHéctor Cañeque-Rufo
Héctor Cañeque-Rufo
AZAgata Zuccaro
Agata Zuccaro
MSMarta Inmaculada Sanz-Cuadrado
Marta Inmaculada Sanz-Cuadrado
FRFederica Ruin
Federica Ruin
ÁOÁngela Olivera-Rodriguez
Ángela Olivera-Rodriguez
MRM.Pilar Ramos-Alvarez
M.Pilar Ramos-Alvarez
Obesity is a global health problem linked to the development of metabolic syndrome (MetS) and comorbidities such as metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). These diseases are characterised by systemic inflammation, lipid accumulation and tissue damage, which contribute to liver fibrosis and dysfunction. Pleiotrophin (PTN), a cytokine known for its role in tissue regeneration and energy metabolism, has emerged as a potential regulator of liver homeostasis. Herein, we demonstrate that Ptn deletion protects against body weight gain, metainflammation and high-fat diet (HFD)-induced MASLD and MASH development. Furthermore, our work uncovers the molecular mechanisms by which PTN may promote lipid synthesis and hepatic extracellular matrix remodelling. Results highlight PTN as a critical modulator of liver metabolism and systemic inflammation in the context of obesity, identifying it as a promising therapeutic target for the treatment of MASLD, MASH and related metabolic disorders, and point to a sexual dimorphism in adaptive metabolic strategies, with females demonstrating a greater degree of protection against the liver-damaging effects of diet-induced obesity. HIGHLIGHTS: Females are more protected against the liver-damaging effects of the high-fat diet (HFD), suggesting a sexual dimorphism in adaptive metabolic strategies. PTN regulates lipid metabolism by promoting lipogenesis and lipid accumulation in liver cells through the activation of AKT and the inhibition of AMPKα; the absence of PTN reverses this process. Deletion of Ptn protects against high-fat diet (HFD)-induced weight gain, systemic inflammation, hepatic lipid accumulation, and the development of steatosis and liver fibrosis. PTN is a key modulator of metabolic, inflammatory and remodelling processes in the liver, and it is proposed as a promising therapeutic target for MASLD, MASH and other metabolic comorbidities. Graphical PTN liver signalling pathway.: acetyl-CoA carboxylase (ACC); 5’ adenosine monophosphate-activated protein kinase (AMPK); protein kinase B (AKT); aquaporin 9 (AQP9); diacylglycerides (DAG); diacylglycerol O-acyltransferase 2 (DGAT2); free fatty acids (FFA); hepatic stellate cell (HSC); insulin receptor (IR); pleiotrophin (PTN); triacylglycerides (TAG).